| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Assumpció Bosch | Q57440827 |
| Miguel Chillon | Q42173138 | ||
| P2093 | author name string | Alba R | |
| P2860 | cites work | Extensive cross-reactivity of adenovirus-specific cytotoxic T cells | Q45888553 |
| Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. | Q45889752 | ||
| Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses | Q46574926 | ||
| Growth of 293 cells in suspension culture. | Q52826380 | ||
| Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice | Q57043130 | ||
| Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells | Q64378303 | ||
| Stable transfer of a mouse dihydrofolate reductase gene into a deficient cell line using human adenovirus vector | Q64379700 | ||
| Immunomodulation with FK506 around the time of intravenous re-administration of an adenoviral vector facilitates gene transfer into primed rat liver | Q64380912 | ||
| A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis | Q64381103 | ||
| Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors | Q64381327 | ||
| Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype | Q64382611 | ||
| "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype | Q64383018 | ||
| Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung | Q73429984 | ||
| Improved vascular gene transfer with a helper-dependent adenoviral vector | Q45877388 | ||
| Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. | Q45880303 | ||
| Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector | Q45882548 | ||
| Replication and packaging of helper-dependent adenoviral vectors | Q45884875 | ||
| Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. | Q45885499 | ||
| Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses | Q45887065 | ||
| Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus | Q45887562 | ||
| X chromosome-linked muscular dystrophy (mdx) in the mouse | Q28589078 | ||
| Characteristics of a human cell line transformed by DNA from human adenovirus type 5 | Q29547863 | ||
| Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. | Q30850268 | ||
| Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor | Q32129558 | ||
| Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. | Q33337331 | ||
| A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia | Q33348516 | ||
| PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile | Q33364520 | ||
| Circumvention of immunity to the adenovirus major coat protein hexon. | Q33783658 | ||
| Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis | Q33804926 | ||
| Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability | Q33834104 | ||
| "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung | Q33841039 | ||
| A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus | Q33952908 | ||
| Production of first generation adenovirus vectors: a review | Q34085243 | ||
| Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. | Q34190967 | ||
| Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector | Q34385773 | ||
| Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression | Q34615481 | ||
| Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia | Q34787537 | ||
| Adenovirus-mediated regulable target gene expression in vivo | Q34807993 | ||
| Optimization of the helper-dependent adenovirus system for production and potency in vivo | Q34996749 | ||
| Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo | Q35149966 | ||
| Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for ch | Q35161530 | ||
| Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy | Q35232341 | ||
| CAR chasing: canine adenovirus vectors-all bite and no bark? | Q35673359 | ||
| Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. | Q35749783 | ||
| A phage integrase directs efficient site-specific integration in human cells | Q35756794 | ||
| Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ | Q35875594 | ||
| A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal | Q35915922 | ||
| Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. | Q35943949 | ||
| Persistence in muscle of an adenoviral vector that lacks all viral genes | Q36018705 | ||
| Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver | Q36145287 | ||
| An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene | Q36163092 | ||
| Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons | Q36557727 | ||
| Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer | Q39588767 | ||
| Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes | Q39592823 | ||
| Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted | Q39642143 | ||
| Variables affecting in vivo performance of high-capacity adenovirus vectors | Q39682415 | ||
| Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. | Q39878778 | ||
| Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo | Q39960801 | ||
| Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors | Q40376983 | ||
| Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses | Q40483401 | ||
| Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors | Q40582642 | ||
| Improved system for helper-dependent adenoviral vector production | Q40619668 | ||
| Lymphocyte responses and cytokines | Q40620203 | ||
| Application of an immunoperoxidase monolayer assay for the detection of arboviral antibodies | Q40651385 | ||
| Optimization of the generation and propagation of gutless adenoviral vectors | Q40663790 | ||
| A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. | Q40675926 | ||
| Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity | Q40785247 | ||
| Development of a FLP/frt system for generating helper-dependent adenoviral vectors | Q40805792 | ||
| Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production | Q40846894 | ||
| Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system | Q40860707 | ||
| Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo | Q40883683 | ||
| New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. | Q41008255 | ||
| Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. | Q41237683 | ||
| FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer | Q41275978 | ||
| Long-term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. | Q42454594 | ||
| Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero | Q42469138 | ||
| Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro | Q42824655 | ||
| Targeting of high-capacity adenoviral vectors | Q43740114 | ||
| Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors | Q44071807 | ||
| Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. | Q44178358 | ||
| Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo | Q44388364 | ||
| NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice | Q44409461 | ||
| Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia | Q44438472 | ||
| In vivo ligand-inducible regulation of gene expression in a gutless adenoviral vector system | Q44476539 | ||
| The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors | Q44476543 | ||
| Autoregulation of 2 micron circle gene expression provides a model for maintenance of stable plasmid copy levels | Q44505948 | ||
| An HSV amplicon-based helper system for helper-dependent adenoviral vectors | Q44523754 | ||
| Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice | Q44673813 | ||
| Early adenoviral gene expression mediates immunosuppression by transduced dendritic cell (DC): implications for immunotherapy using genetically modified DC. | Q44735899 | ||
| Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. | Q44765402 | ||
| Helper-dependent adenoviral vectors containing modified fiber for improved transduction of developing and mature muscle cells | Q44771050 | ||
| Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. | Q44809129 | ||
| Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization | Q44850205 | ||
| Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus | Q45036081 | ||
| Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo | Q45855028 | ||
| High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity | Q45855434 | ||
| PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver | Q45855754 | ||
| DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. | Q45856685 | ||
| Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration | Q45862335 | ||
| Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin | Q45862401 | ||
| Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration | Q45866667 | ||
| Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector | Q45866962 | ||
| Gene Therapy for Hemophilia B: Host Immunosuppression Prolongs the Therapeutic Effect of Adenovirus-Mediated Factor IX Expression | Q45866981 | ||
| Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice | Q45871591 | ||
| Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector | Q45872994 | ||
| Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain | Q45874048 | ||
| Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL. | Q45877059 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| gene therapy | Q213901 | ||
| P304 | page(s) | S18-27 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Gutless adenovirus: last-generation adenovirus for gene therapy | |
| P478 | volume | 12 Suppl 1 |
| Q37596293 | A cut above the rest: targeted genome editing technologies in human pluripotent stem cells |
| Q38308865 | Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery |
| Q41931475 | Advancements in the design and scalable production of viral gene transfer vectors. |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q38187715 | All roads lead to induced pluripotent stem cells: the technologies of iPSC generation. |
| Q33911195 | Altering the Ad5 packaging domain affects the maturation of the Ad particles. |
| Q39249412 | An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs |
| Q37945220 | An update on canine adenovirus type 2 and its vectors |
| Q64073539 | Autophagy regulates lipid metabolism through selective turnover of NCoR1 |
| Q36655133 | Cancer gene therapy targeting angiogenesis: an updated review |
| Q35142325 | Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes |
| Q37698448 | Corrective GUSB transfer to the canine mucopolysaccharidosis VII brain |
| Q36219639 | Corrective GUSB transfer to the canine mucopolysaccharidosis VII cornea using a helper-dependent canine adenovirus vector |
| Q64930555 | Current Landscape of Heart Failure Gene Therapy. |
| Q38788217 | Current Methods in Cardiac Gene Therapy: Overview |
| Q38099680 | Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives |
| Q37677605 | Delivering the goods: viral and non-viral gene therapy systems and the inherent limits on cargo DNA and internal sequences |
| Q99724691 | Delivery Approaches for Therapeutic Genome Editing and Challenges |
| Q39754943 | Detection of adeno- and lentiviral (HIV1) contaminations on laboratory surfaces as a tool for the surveillance of biosafety standards |
| Q40121555 | Differential amplification of adenovirus vectors by flanking the packaging signal with attB/attP-PhiC31 sequences: implications for helper-dependent adenovirus production. |
| Q35943638 | Effect of rapamycin on immunity induced by vector-mediated dystrophin expression in mdx skeletal muscle |
| Q33770522 | Effective modifications for improved homologous recombination and high-efficiency generation of recombinant adenovirus-based vectors |
| Q34632501 | Effects of irradiating adult mdx mice before full-length dystrophin cDNA transfer on host anti-dystrophin immunity |
| Q37256197 | Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance |
| Q36236887 | Elevation of intraocular pressure in rodents using viral vectors targeting the trabecular meshwork |
| Q40080564 | Emerging Gene Therapies for Genetic Hearing Loss |
| Q33307471 | Exploring DNA damage responses in human cells with recombinant adenoviral vectors. |
| Q39934266 | First step in characterization of cis-acting sequences involved in fowl adenovirus 1 (CELO) packaging and its effect on the development of a helper-dependent vector strategy |
| Q39171777 | Foamy virus-adenovirus hybrid vectors for gene therapy of the arthritides. |
| Q40080450 | Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity |
| Q35186312 | Gene Therapies for Cancer: Strategies, Challenges and Successes |
| Q64093774 | Gene Therapy Leaves a Vicious Cycle |
| Q51846343 | Gene Therapy Used in Cancer Treatment. |
| Q52721830 | Gene Therapy With Regulatory T Cells: A Beneficial Alliance. |
| Q33917592 | Gene delivery with viral vectors for cerebrovascular diseases |
| Q40548581 | Gene therapy based in antimicrobial peptides and proinflammatory cytokine prevents reactivation of experimental latent tuberculosis. |
| Q83556143 | Gene therapy for heart failure |
| Q33881920 | Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. |
| Q38016275 | Gene therapy for the treatment of chronic peripheral nervous system pain |
| Q36953151 | Gene therapy for the treatment of heart failure: promise postponed |
| Q36789527 | Gene therapy for type I glycogen storage diseases |
| Q36748645 | Gene therapy used for tissue engineering applications. |
| Q36698991 | Gene transfer for congestive heart failure: update 2013. |
| Q90505891 | Genetic Therapies for Hearing Loss: Accomplishments and Remaining Challenges |
| Q36828787 | Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice |
| Q40301190 | Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication |
| Q27488744 | Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma |
| Q35085363 | Implications of the innate immune response to adenovirus and adenoviral vectors |
| Q37945219 | Improving adenovirus based gene transfer: strategies to accomplish immune evasion |
| Q45120288 | Infection of primary hepatocytes with adenoviral vectors alters biliary lipid metabolism |
| Q38051768 | Insulin gene therapy from design to beta cell generation. |
| Q38023422 | Latest insights on adenovirus structure and assembly. |
| Q40075764 | Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes |
| Q90974934 | No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants |
| Q55365677 | One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors. |
| Q36852196 | Opportunities for treating chronic hepatitis B and C virus infection using RNA interference |
| Q24635276 | PEGylated Adenoviruses: From Mice to Monkeys |
| Q35238390 | Perinatal gene transfer to the liver |
| Q90601290 | Practical aspects of inner ear gene delivery for research and clinical applications |
| Q26781432 | Progresses towards safe and efficient gene therapy vectors |
| Q38578275 | Prospect and progress of gene therapy in treating atherosclerosis |
| Q34657942 | RNA interference: from basic research to therapeutic applications |
| Q37288582 | Rapid assembly of customized TALENs into multiple delivery systems |
| Q36811133 | Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. |
| Q36949857 | Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways |
| Q92719472 | Recombinant adenovirus carrying a core neutralizing epitope of porcine epidemic diarrhea virus and heat-labile enterotoxin B of Escherichia coli as a mucosal vaccine |
| Q28076639 | Replicon RNA Viral Vectors as Vaccines |
| Q41923573 | Roadmap for an early gene therapy for cystic fibrosis airway disease |
| Q91639216 | Role of Nampt overexpression in a rat model of Hashimoto's thyroiditis and its mechanism of action |
| Q45367025 | Self-inactivating helper virus for the production of high-capacity adenoviral vectors |
| Q51828637 | Targeted gene modification in mouse ES cells using integrase-defective lentiviral vectors. |
| Q37878086 | Targeted gene therapy for the treatment of heart failure |
| Q37550406 | Targeting sarcoplasmic reticulum calcium ATPase by gene therapy |
| Q37969195 | The Sleeping Beauty transposon system for clinical applications |
| Q58133497 | The Use of Viral Vectors in Introducing Genes into Agricultural Animal Species |
| Q37445093 | The companions: regulatory T cells and gene therapy. |
| Q38714835 | The transgenic animal platform for biopharmaceutical production |
| Q38262028 | The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue |
| Q42223027 | Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver |
| Q91768182 | Unravelling Receptor and RGD Motif Dependence of Retargeted Adenoviral Vectors using Advanced Tumor Model Systems |
| Q37615161 | Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). |
| Q38195650 | Vectorology and factor delivery in induced pluripotent stem cell reprogramming. |
| Q34315475 | Viral and nonviral delivery systems for gene delivery |
| Q79768923 | [Role of gene therapy in trauma and orthopedic surgery] |
Search more.